IRSF RETT SYNDROME SCIENTIFIC MEETING: NACCELERATING DISCOVERIES



PRESENTED BY



AGENDA

(All times: Central Time, United States)

| TUESDAY, APRIL 26 | |
|---|---|
| 12:00 pm | Registration |
| 1:00 pm | Welcome |
| 1:05 pm | Keynote Lecture: MeCP2 as a microsatellite DNA binding protein – Ali Hamiche, PhD (IGBMC) |
| 1:35 pm | Oral Presentations |
| | Single-molecule visualization of the interaction between MeCP2 and chromatin – Gabriella Chua (The Rockefeller University) |
| | Pathophysiological length variation, structure, and phase separation of polyA repeats in the NTD and TRD of MeCP2 – Ferdinando Fiumara, MD, PhD (University of Torino) |
| | Transcriptomic insights into the etiology of Rett syndrome – Daniel Connolly (University of Pennsylvania) |
| 2:35 pm | Poster Flash Talks |
| 2:55 pm | BREAK |
| 3:15 pm | Keynote Lecture: X-chromosome reactivation - |
| | Vincent Pasque, PhD (University of Leuven) |
| 3:45 pm | Oral Presentations |
| | Use of ultrasound-based technology to optimize brain gene therapy treatment of mouse models of Rett syndrome – Jean-Christophe Roux, PhD (Aix Marseille Université) |
| | Safety and Biodistribution Assessment in Non-human Primates (NHPs) of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome – Suyash Prasad (Taysha Gene Therapies) |
| | Non-invasive interventions may synergistically enhance MECP2 gene therapy – Sarah Sinnett, PhD (University of Texas Southwestern Medical Center) |
| 4:45 pm | Poster Flash Talks |
| 5:00-6:30 pm Poster Session and Reception | |

7:30-9:00 pm Breakout Sessions

AGENDA

(All times: Central Time, United States)

WEDNESDAY, APRIL 27 7:00 am **Continental Breakfast** 8:00 am Welcome 8:05 am Keynote Lecture: Using human organoids to understand aspects of Rett syndrome -Bennet Novitch, PhD (UCLA) 8:35 am **Oral Presentations** A high throughput screen platform for studying Rett syndrome – Qiang Chang, PhD (University of Wisconsin-Madison) • L1-mediated inflammation in Rett syndrome – Alysson Muotri, PhD (UCSD) • Mitochondrial dynamics and astrocyte contribution to development of Rett pathophysiology in human ESC derived cerebral organoids - Daniella Tomasello, PhD (Whitehead Institute for Biomedical Research) • Overview of rodent models - Rodney Samaco, PhD (Baylor College of Medicine) • A comparative longitudinal study of Magnetic Resonance Imaging in the brain of different Mecp2 deficient mouse models sheds some light on the brain pathology and confirms the limit of using a single mouse model in pre-clinical studies -Nicoletta Landsberger, PhD (University of Milan) 10:15 am BREAK 10:40 am Keynote Lecture: Evoked potentials in mouse models and humans -Eric Marsh, MD, PhD (CHOP Research Institute) 11:10 am **Oral Presentations** Altered adaptation of somatosensory evoked activity reveals deficits in cortical plasticity in a mouse model of Rett syndrome -Kerry Delaney, PhD (University of Victoria) Evaluation of the therapeutic potential of ketamine in a mouse model of Rett syndrome – Michelle Piazza (Vanderbilt University) Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome - Colleen Niswender, PhD (Vanderbilt University) Potentiation of mGluR(7) rescues neurophysiological features in a mouse model of **Rett Syndrome –** Hongwei Dong, PhD (Vanderbilt University Medical Center) 12:30 pm Lunch (Box lunch provided)

AGENDA (All times: Central Time, United States)

WEDNESDAY, APRIL 27

1:30 pm Keynote Lecture: Natural History Study – Jeff Neul, MD, PhD (Vanderbilt Kennedy Center) 2:00 pm **Oral Presentations** • A Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire in children and adults - Walter Kaufmann, MD (Anavex Life Sciences Corp.) • Rett syndrome in adulthood: the caregiver perspective - Kristin Phillips (Taysha Gene Therapies) BREAK 2:40 pm 3:00 pm Keynote Lecture: Gait Analysis in Rett syndrome -Bernhard Suter, MD (Baylor College of Medicine) **Oral Presentations** 3:30 pm • Rett Syndrome: Quantifying gross motor skills and the effect of physical therapy -Briana Czerwinski, DPT (Kennedy Krieger Institute) • Efficacy and safety of trofinetide for the treatment of Rett syndrome: results from the pivotal phase 3 LAVENDER study - Jeff Neul, MD, PhD (Vanderbilt Kennedy Center) **Breakout Session Read Outs** 4:10 pm 5:00 pm Adjourn - Cocktail Reception with Families